Login:
 
Lockyer M. C-peptide testing can identify risk of hypoglycaemia in insulin-treated type 2 diabetes. Practitioner May 2018;262(1815): 8-9

C-peptide testing can identify risk of hypoglycaemia in insulin-treated type 2 diabetes

22 May 2018Pais-up subscribers

Low levels of C-peptide were associated with greater glucose variability and hypoglycaemia in type 2 diabetes patients on insulin,a UK study has found.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .